ESMO 2023 | Targeted therapies for cholangiocarcinoma in the second line setting

Lorenza Rimassa, MD, Humanitas University, Milan, Italy, comments on the development of targeted therapies for patients with cholangiocarcinoma (CCA) pre-treated with cisplatin and gemcitabine. Pemigatinib and futibatinib have both been approved for FGFR2-mutant bile duct cancer and ivosidenib has been approved for CCA with an IDH1 mutation. Phase II trials have additionally assessed trastuzumab deruxtecan and pertuzumab with trastuzumab in HER-2-mutant CCA. Trametinib has also been investigated to treat BRAF-mutant CCA. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.